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Summary
Aims:	 KATP	 ion	 channels	 play	 a	 key	 role	 in	 glucose-	stimulated	 insulin	 secretion.	
However,	many	drugs	block	KATP as “off targets” leading to hyperinsulinaemia and 
hypoglycaemia.	As	such	drugs	are	often	lipophilic,	the	aim	was	to	examine	the	rela-
tionship between drug lipophilicity (P) and IC50	for	KATP	block	and	explore	if	the	IC50’s 
of statins could be predicted from their lipophilicity and whether this would allow 
one to forecast their acute action on insulin secretion.
Materials and methods:	A	meta-	analysis	of	26	lipophilic,	nonsulphonylurea,	blockers	
of	KATP	was	performed.	From	this,	 the	 IC50’s for pravastatin and simvastatin were 
predicted	and	then	tested	experimentally	by	exploring	their	effects	on	KATP channel 
activity	via	patch-	clamp	measurement,	calcium	imaging	and	insulin	secretion	in	mu-
rine beta cells and islets.
Results:	Nonsulphonylurea	drugs	inhibited	KATP	channels	with	a	Log	IC50 linearly re-
lated	to	their	logP.	Simvastatin	blocked	KATP with an IC50	of	25	nmol/L,	a	value	inde-
pendent	 of	 cytosolic	 factors,	 and	 within	 the	 range	 predicted	 by	 its	 lipophilicity	
(21-	690	nmol/L).	10	μmol/L	pravastatin,	predicted	IC50	0.2-	12	mmol/L,	was	without	
effect	 on	 the	KATP	 channel.	At	 10-	fold	 therapeutic	 levels,	 100	nmol/L	 simvastatin	
depolarized	the	beta-	cell	membrane	potential	and	stimulated	Ca2+	influx	but	did	not	
affect	insulin	secretion;	the	latter	could	be	explained	by	serum	binding.
Conclusions:	The	logP	of	a	drug	can	aid	prediction	for	 its	ability	to	block	beta-	cell	
KATP	ion	channels.	However,	although	the	IC50	for	the	block	of	KATP by simvastatin 
was	predicted,	the	difference	between	this	and	therapeutic	levels,	as	well	as	serum	
sequestration,	explains	why	hypoglycaemia	is	unlikely	to	be	observed	with	acute	use	
of this statin.
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1  | INTRODUC TION
The	role	of	the	pancreatic	beta-	cell	KATP ion channel in the regula-
tion of insulin secretion is well characterized.1	An	extensive	range	
of	 compounds	 is	 known	 to	 block	 the	 KATP channel; canonically 
these	 are	 sulphonylureas,	 such	 as	 tolbutamide,2	 gliclazide,3 glip-
izide4 and glibenclamide2,4;	and	glitinides,	such	as	meglitinide2 and 
repaglinide.5	The	ability	of	these	drugs	to	selectively	block	KATP in 
pancreatic beta cells underlies their use in the treatment of hyper-
glycaemia.4	 However,	 many	 other	 structurally	 diverse	 drugs	 can	
also	block	KATP	as	an	“off	 target”;	where	 inadvertent	block	of	 the	
pancreatic	beta-	cell	KATP channel can lead to the adverse effects 
of	hyperinsulinaemia	and	hypoglycaemia	seen	in	the	clinic,	for	ex-
ample following over dosage with quinolones in the treatment of 
malaria.6	Indeed,	most	studies	that	have	investigated	the	ability	of	
nonsulphonylurea	drugs	to	block	beta-	cell	KATP channel activity and 
stimulate insulin secretion have arisen from clinical reports of ad-
verse hypoglycaemic episodes during their acute usage; as reported 
for	 thiazolidinediones,7,8	 quinolones,6,9 fluoroquinolones10 and 
pheniramines.11	Although	no	obvious	common	structural	chemical	
moieties	underlie	the	“off	target”	action	of	these	drugs,	they	do	all	
share	the	common	property	of	lipophilicity.	As	a	trend	between	the	
potency	to	block	KATP and lipophilicity is noted for barbiturates
12 
whether	this	also	extends	to	other,	nonsulphonylurea,	blockers	of	
KATP	is	unknown.
Statins,	that	is	3-	hydroxy-	3-	methyl	glutaryl	coenzyme	A	(HMG-	
CoA)	 reductase	 inhibitors,	 are	 compounds	 currently	 used	 to	 treat	
hypercholesterolaemia. These drugs widely differ in their water 
solubility,	and	clinical	trials	have	highlighted	an	association	between	
their	 lipophilicity	and	risk	of	glucose	intolerance	and	diabetes	with	
chronic use13;	 however,	 these	 drugs,	 unlike	 other	 lipophilic	 drugs,	
are not reported to produce hypoglycaemia with acute use. The 
question	arises	as	to	whether	statins	can	block	KATP and if lipophilic-
ity is indeed a useful predictor for the potency of a compound to 
block	 this	 ion	 channel?	 If	 so,	we	can	 then	ask	 the	questions	as	 to	
whether statins promote Ca2+	influx,	and	if	so,	query	their	inability	
to	stimulate	insulin	release	in	vivo?
The primary aim of this study was to determine the relationship 
between	drug	lipophilicity	and	block	of	KATP	by	a	meta-	analysis	and	
then to test whether this relationship could reliably predict the po-
tency of other drugs to affect the activity of pancreatic β-	cell	KATP 
channels and insulin secretion.
2  | MATERIAL S AND METHODS
2.1 | Relationship between Log IC50 and the logP  
for the block of KATP
The	Log	IC50	of	26	compounds	that	block	beta-	cell	KATP channel ac-
tivity	was	extracted	from	publications	given	in	Figure	1.	IC50 values 
were	previously	determined	by	 inside-	out	or	 standard	whole-	cell	
patch-	clamp	recording	methods	under	similar	experimental	condi-
tions of temperature and pH and the presence of intracellular Mg2+; 
except	where	Mg2+ did not affect drug action. Only compounds 
with	logP	values,	where	P	is	the	octanol/water	partition	coefficient,	
>0	were	included	to	avoid	situations	where	the	drug	would	exist	in	
a	predominantly	charged	state	at	physiological	pH	and	inhibit	KATP 
by	an	open-	channel	block	mechanism.	Experimentally	determined	
logP	values	(Log	D	at	pH	7.4,)	were	extracted	from	www.DrugBank.
ca and were confirmed from the original source references to be 
within	 the	physiological	pH	 range	7-	8	 to	account	 for	neutral	 and	
ionized	species	in	the	aqueous	phase.	When	an	experimental	logP	
was	unavailable,	as	was	the	case	for	cibenzoline,	ciclazindol,	engli-
tazone,	 2-	n-	hexyl-	4-	benzoxazine,	 temafloxacin,	 terfenadine	 and	
Triton	X-	100,	it	was	calculated	from	quantitative	structural	activity	
relationship	calculations	 (QSAR)	at	www.Chemicalize.com.	To	de-
termine	whether	a	relationship	existed	between	Log	IC50 and logP 
Pearson	correlation	was	performed,	and	the	data	were	described	
by	 linear	 regression	with	PRISM	version	7	 (GraphPad,	San	Diego,	
CA,	USA).
2.2 | Preparation of β cells
Primary pancreatic β cells were dissociated from islets of male CD1 
mice	 (30-	50	g;	 3-	6	months	 old).14	 All	 animal	 care	 and	 experimen-
tal	procedures	were	 carried	out	 in	 accordance	with	either	 the	UK	
F IGURE  1 Relationship	between	Log	IC50	of	KATP and logP 
values	for	compounds	that	block	beta-	cell	KATP channel activity. 
Key:	Am,	amantadine37;	BDM,	2,3-	butanedione	monoxime18; 
Cib,	cibenzoline38;	Cic,	ciclazindol28;	Clo,	clonidine9;	Dis,	
disopyramide11,27;	Eng,	englitazone8;	Gat,	gatifloxacin10;	gen,	
genistein32;	Glp,	glipizide;	Gly,	glibenclamide4;	Glc,	gliclazide3;	Hal,	
haloperidol29;	Hex,	2-	n-	hexyl-	4-	benzoxazine30;	Mef,	mefloquine6; 
Meg,	meglitinide4;	Peb,	pentobarbitone12;	Phb,	phenobarbitone12; 
Phe,	phentolamine20,31;	Qun,	quinine9;	Rep,	repaglinide5;	Rog,	
rosiglitazone7;	Seb,	secobarbitone12;	Sim,	simvastatin;	Spa,	
sparteine37;	Tem,	temafloxacin10;	Ter,	terfenadine39;	Thp,	
thiopentone12;	Tb,	tolbutamide4;	Trg,	troglitazone40;	TX,	Triton	X-	
100.24	Log	IC50 values are from respective references. logP values 
are	as	published	on	DrugBank,	except	for	cibenzoline,	englitazone	
and	Triton	X-	100,	which	were	calculated	using	Chemicalize.	Solid	
line is linear regression fit (r2	.78)	of	the	equation:	Log	IC50 =  
−logP−2.22	to	only	data	indicated	by	●.	Dotted	lines	are	the	
95%	confidence	intervals.	Log	IC50 determined in the absence of 
intracellular Mg2+	are	suffixed	by	*
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Home	Office	Animals	(Scientific	Procedures)	Act	(1986)	or	Swedish	
ethical	 review	board.	Mice	were	 killed	 by	 cervical	 dislocation	 and	
exsanguinated	by	decapitation.	Islets	were	extracted	either	by	type	
V	collagenase	(Sigma)	or	Liberase	TM	(Roche)	digestion.	Single	cell	
was	 liberated	by	 dissociation	with	 trypsin-	EDTA14 and maintained 
in	RPMI	1640	media,	 supplemented	with	11	mmol/L	glucose,	10%	
FBS,	 10	mmol/L	 HEPES,	 50	μg/mL	 penicillin	 and	 50	μg/mL	 strep-
tomycin	 and	 kept	 up	 to	 2	days	 in	 a	 humidified	 atmosphere	 of	 5%	
CO2/95%	at	37°C.	To	reduce	and	replace	animal	usage,	the	murine	
β-	cell	 line	MIN615,16	was	 used	 to	 test	 the	 effect	 of	 drugs	 on	KATP 
in	inside-	out	patches	as	well	as	intracellular	Ca2+	levels.	MIN6	cells,	
passage	35-	40,	were	maintained	as	for	the	primary	β cells but with-
out antibiotics.16
2.3 | Insulin measurement
Islets	were	 recovered	 in	11	mmol/L	glucose	RPMI	 for	2	hours	and	
then	incubated	for	45	minutes	in	3	mmol/L	glucose	Krebs	buffer	(in	
mmol/L):	120	NaCl,	4.7	KCl,	2.5	CaCl2,	1.2	KH2PO4,	1.2	MgSO4,	25	
NaHCO3	and	10	HEPES	supplemented	with	0.1%	BSA,	prior	to	ex-
perimentation.	Islets	in	groups	of	10	were	picked	at	random	and	in-
cubated	at	37°C	for	1	hour	under	conditions	indicated.	Supernatant	
was	collected,	protease	activity	inhibited	with	0.05	mg/mL	aprotinin	
(Sigma-	Aldrich),	and	insulin	measured	by	ELISA	(Mercodia,	Sweden).	
Insulin	is	expressed	in	relation	to	total	protein	content	(Pierce	BCA	
protein	kit;	Thermo	Scientific,	USA).
2.4 | Intracellular Ca2+ measurement
Intracellular Ca2+,	 [Ca2+]i,	was	monitored	by	epifluorescent	micros-
copy	 with	 FLUO-	4	 as	 described	 previously.14	 Experiments	 were	
performed	in	a	modified	Hanks	solution	(in	mmol/L):	137	NaCl,	5.6	
KCl,	 1.2	MgCl2,	 2.6	CaCl2,	 1.2	NaH2PO4,	 4.2	NaHCO3,	 10	HEPES	
(pH	7.4	with	NaOH)	and	2	mmol/L	glucose.	Images	were	captured	at	
1	Hz	with	a	CoolSNAP	HQ2	camera	(Photometrics,	UK).	Only	cells	
that responded to tolbutamide (20 μmol/L)	were	chosen	for	analy-
sis.	Regions	of	 interest	 (ROI)	were	 corrected	 for	background	 fluo-
rescence	by	subtraction,	the	average	fluorescence	intensity	per	ROI	
calculated	and	normalized	to	that	measured	with	an	extracellular	[K+] 
of	 50	mmol/L;	 a	 condition	 that	 elicits	maximal	 voltage-	gated	Ca2+ 
influx.
2.5 | Measurement of KATP ion channel activity
KATP	channel	activity	in	cell-	attached	experiments	was	measured	in	
Hanks	solution,	and	this	allows	the	membrane	potential	(Vm)	to	vary	
such that Vm changes (ΔVm) can also be estimated from fluctuations 
in	the	single-	channel	current	amplitude,	Δi,	via	ΔVm = (Δi)/γ; where γ 
is	the	KATP	single-	channel	chord	conductance.	To	arrest	rundown	of	
excised	KATP	channels,
17,18	concentration-	effect	 relationships	were	
made	with	 inside-	out	 patches	 in	 a	 low	 intracellular	Mg2+ solution 
(in	mmol/L):	KCl	 140,	CaCl2	 4.6,	 EDTA	10,	HEPES	10	 (free	 [Mg
2+] 
<6	nmol/L;	 free	 [Ca2+]	 <30	nmol/L;	 pH	 7.2	 with	 KOH).	 For	 both	
configurations,	the	pipette	solution	contained	(in	mmol/L)	140	KCl,	
CaCl2	2.6,	MgCl2	1.2	and	HEPES	10	(pH	7.4	with	NaOH).
Patch	pipettes,	resistances	2-	4	MΩ,	were	drawn	from	GC150TF	
capillary	glass	(Harvard	Instruments),	coated	with	dental	wax	(Kerr)	
and fire polished before use. Currents were measured using an 
Axopatch	1D	patch-	clamp	amplifier	(Molecular	Devices).	The	zero-	
current potential of the pipette was adjusted with the pipette in the 
bath	just	before	seal	establishment.	No	corrections	have	been	made	
for	 liquid	 junction	 potentials	 (<4	mV).	 Currents	were	 low-	pass	 fil-
tered	at	2	kHz	 (−3	db,	8	pole	Bessel)	and	digitized	at	10	kHz	using	
pClamp	 8.3	 (Axon	 Instruments,	 Foster	 City,	 USA).	 Single-	channel	
data	 were	 analysed	 with	 half-	amplitude	 threshold	 techniques	 as	
implemented	 in	 Clampfit	 Ver.	 10.6	 (Axon	 Instruments).	 For	 cell-	
attached	recording,	the	pipette	potential,	Vp,	was	held	at	0	mV	and	
for	inside-	out	patches	+70	mV.	Channel	activity,	NPo,	was	recorded	
for	3-	minute	periods,	first	in	basal	then	after	a	10-	minute	incubation	
in	drug.	To	control	for	intrapatch	variability	in	basal	NPo,	the	effects	
of	drug	are	quantified	as	the	fraction	of	basal	NPo	measured	prior	
to compound addition.
To	 monitor	 the	 time	 course	 of	 block	 and	 recovery	 of	 KATP 
channel	 activity	 by	 simvastatin,	 standard	 whole	 cell	 (WC-	KATP) 
was used as described.17,18	 For	 these	 experiments,	 the	 pipette	
contained the low Mg2+ intracellular solution and cells continu-
ously	perifused	with	Hanks	solution.	KATP activity was monitored 
by the current elicited in response to 10 mV pulses of alternate 
polarity,	 200	ms	 duration,	 applied	 at	 0.5	Hz	 from	 a	 holding	 po-
tential	of	−70	mV.17,18	Electrophysiological	experiments	were	per-
formed	at	21-	23°C.
Simvastatin and pravastatin were obtained from Tocris 
Bioscience,	 Bristol,	 UK.	 Simvastatin	 was	 dissolved	 in	 ethanol	 or	
DMSO,	pravastatin	 in	H2O. Drug additions were made from serial 
diluted	stocks	such	that	the	vehicle	was	always	applied	at	the	same	
final	concentration:	0.1%	vol/vol.
2.6 | Statistical analysis
Statistical	 analysis	 was	 performed	 using	 PRISM,	 and	 data	 were	
checked	for	normality	with	the	D’Agostino	&	Pearson	omnibus	nor-
mality	 test	and	the	appropriate	statistical	 test	used.	Unless	stated	
otherwise,	pairwise	comparison	was	by	unpaired	T	test	or	Wilcoxon	
signed-	rank	 test	 and	multiple	 comparisons	by	ANOVA	or	Kruskal-	
Wallis.	 The	 concentration-	response	 for	 KATP	 block	 by	 simvastatin	
was quantified by fitting the data with the equation:
where Y	is	the	fractional	KATP	activity	relative	to	control,	Ymax,	h 
is	the	slope	index,	[S]	is	the	simvastatin	concentration,	and	IC50 is the 
concentration	that	produces	half-	maximal	 inhibition.	IC50 was esti-
mated	from	the	block	of	WC-	KATP by a single drug concentration via 
rearrangement of this equation with h values of 1 for tolbutamide4 
and 0.7 for simvastatin.
Y=Ymax∕(1+ ([S]∕IC50)
h),
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Data	are	given	as	the	mean	±	SEM	or	median	with	5%-	95%	con-
fidence	 intervals	 (C.I.),	 with	 n	 the	 number	 of	 experimental	 units.	
Statistical significance is defined as P	<	.05	 and	 is	 flagged	 as	 *	 in	
graphics.
3  | RESULTS
3.1 | Relationship between Log IC50 and the logP  
for the block of KATP
Figure	1	shows	that,	with	exception	of	the	second-	generation	sul-
phonylureas	(glipizide	and	glibenclamide),	the	potency	(Log	IC50) of 
drugs	 to	 block	 KATP channel activity was linearly correlated with 
lipophilicity	(logP)	with	a	slope	of	−1	(1.26	to	−0.74,	95%	C.I.)	and	
a	Log	y	intercept	of	−2.23	(−3.0	to	−1.4	95%	C.I.;	Pearson	r	=	−.81,	
P	<	.001).	From	this	regression	analysis,	simvastatin	(logP	4.68)	was	
predicted to have an IC50	 between	21	 and	690	nmol/L	 (95%	C.I.)	
and	 pravastatin	 (logP	 0.59)	 an	 IC50	 between	 0.2	 and	 12	mmol/L	
(95%	C.I.)
3.2 | Simvastatin potently blocks KATP 
channel activity
In	the	absence	of	glucose,	cell-	attached	patches	displayed	single-	
channel currents with biophysical metrics characteristic for 
KATP	 channels	 (Figure	2A):	 single-	channel	 current	 amplitude	 (i)	
4.7	±	0.2	pA,	chord	conductance	(γ)	~67	±	2	pS,	burst	kinetics	with	
a	mean	 open-	channel	 dwell	 time	 of	 1.2	±	0.1	ms	 (n	=	10).	Within	
3	minutes	 of	 perifusion,	 5	mmol/L	 glucose	 significantly	 reduced	
NPo	by	56%	 (33%-	87%,	95%	C.I.;	n	=	10)	and	depolarized	Vm	by	
5.2	±	0.8	mV	 (n	=	10;	 Figure	2B);	 observations	 consistent	 with	 a	
KATP channel identity.
16,18-20	Addition	of	10	μmol/L	simvastatin	in-
hibited	the	remaining	channel	activity	by	a	further	76%	(39%-	98%,	
95%	C.I.;	 n	=	5;	Figure	2C),	 an	action	associated	with	depolariza-
tion	of	Vm	by	31	±	6	mV	(n	=	6);	effects	consistent	with	KATP	block.	
The	vehicle	control,	0.1%	vol/vol	DMSO,	neither	affected	NPo	nor	
Vm (n = 5).
Comparable	results	were	observed	 in	cell-	attached	patches	but	
in	the	absence	of	glucose,	10	μmol/L	simvastatin	 (P	<	.05,	ANOVA),	
but not 10 μmol/L	pravastatin,	significantly	decreased	KATP channel 
activity	 and	 depolarized	 Vm	 (31	±	5	mV;	 n	=	9)	 relative	 to	 vehicle	
controls	 (Figure	3A).	To	check	that	DMSO	itself	did	not	modify	the	
effect of simvastatin; 10 μmol/L	simvastatin	still	 significantly	 inhib-
ited	KATP	channel	activity	with	ethanol	(0.1%	vol/vol)	as	the	vehicle	
(Figure	3A).	In	inside-	out	patches	from	primary	beta	cells	(Figure	2D-	
E),	 10	μmol/L	 simvastatin,	 but	 not	 pravastatin,	 inhibited	 channel	
activity	 (Figure	3A).	 In	 inside-	out	 patches,	 simvastatin	 neither	 af-
fected	single-	channel	current	amplitude	nor	open-	channel	dwell	time	
(Figure	2D-	F)	but	inhibited	KATP	channel	activity	(Figure	3B)	with	an	
IC50	of	26	nmol/L	(18-	37	nmol/L,	95%	C.I.)	and	h	of	0.73	(0.53-	0.94,	
95%	C.I.).	These	data	demonstrate	 that	 the	effect	of	simvastatin	 is	
independent	of	glucose	metabolism,	intracellular	Mg2+ and cytosolic 
factors. 20 μmol/L	tolbutamide	and	100	nmol/L	simvastatin	inhibited	
KATP	channel	activity	in	standard	whole	cell	by	43	±	3.3%	(n	=	9)	and	
47	±	3.1%,	 respectively	 (n	=	5;	 Figure	3C-	E).	 The	 IC50 for simvasta-
tin	 estimated	 from	 the	 whole-	cell	 data:	 31	nmol/L	 (20-	42	nmol/L,	
95%	C.I.)	was	almost	 identical	 to	that	measured	for	the	 IO	patches	
(26	nmol/L;	Figure	3F).	Both	the	onset	and	washout	of	tolbutamide	
block	 were	 complete	 within	 1	minute,	 unlike	 that	 for	 simvastatin,	
which	took	at	least	10	minutes	to	achieve	steady-	state	block	and	was	
irreversible.
3.3 | Simvastatin stimulates Ca2+ influx
In	 the	 presence	 (Figure	4A),	 but	 not	 the	 absence	 (Figure	4D),	 of	
2	mmol/L	 glucose,	 100	nmol/L	 simvastatin	 elicited	 an	 increase	 in	
[Ca2+]i similar to that with 20 μmol/L	 tolbutamide	 (Figure	4A).	 An	
observation	of	an	increase	in	[Ca2+]i	by	100	nmol/L	simvastatin	over	
a	 15-	minute	 incubation	had	 an	odds	 ratio	 of	 10.8	 (3-	39,	 95%	C.I.,	
P = .0001) relative to its DMSO vehicle control.
3.4 | Simvastatin failed to affect insulin secretion
Neither	 pravastatin	 nor	 simvastatin	 affected	 basal	 or	 glucose-	
stimulated insulin secretion from mouse pancreatic islets at the 2 
concentrations	 tested	 (100	nmol/L	 and	 1	μmol/L;	 Figure	5A,B).	 As	
the failure of simvastatin to effect insulin secretion may be due 
to	 serum	 sequestration,	 the	 effect	 of	 BSA	 on	 the	 efficacy	 of	 the	
drug	 to	block	KATP	was	explored.	 In	whole-	cell	 records,	0.5%	BSA	
significantly decreased the efficacy of 1 μmol/L	simvastatin	by	10-	
fold	to	an	amount	similar	to	that	found	with	100	nmol/L	of	the	drug	
(Figure	5C).	In	cell-	attached	patches,	0.1%	BSA	abolished	the	ability	
of	100	nmol/L	simvastatin	to	inhibit	KATP	activity	(NPo)	and	depolar-
ize	Vm	(Figure	5D).
4  | DISCUSSION
The	Log	IC50	for	the	block	of	KATP	by	lipophilic	drugs,	except	for	the	
second-	generation	 sulphonylureas,	 was	 positively	 correlated	 with	
their	logP.	Moreover,	this	relationship	accurately	predicted	the	Log	
IC50	for	the	block	of	KATP by simvastatin and pravastatin.
The	observation	that	Log	IC50	of	KATP	block	by	a	drug	is	related	
to its logP has already been described for barbiturates.12	However,	
we now show that this relationship holds for a far greater range of 
structurally	 diverse	 compounds.	 Two	 compounds,	 englitazone	 and	
ciclazindol,	fell	outside	the	95%	confidence	limits	of	the	linear	model,	
and the reasons for this are unclear but may relate to the accuracy 
of	the	logP	values	used.	The	95%	confidence	intervals	of	our	linear	
model	 encompass	 a	 Log10	 range	 from	1	 to	 2;	with	 a	 100-	fold	 dif-
ference between the confidence limits for the smallest and largest 
logP	values,	but	only	a	10-	fold	difference	at	its	mid-	point	where	the	
majority of data lay.
The pancreatic β-	cell	KATP channel is an octamer composed of 4 
Kir6.2	and	4	SUR1	subunits,	the	latter	associated	with	the	specific	
     |  5 of 10REAL Et AL.
binding of sulphonylureas.21-23	 Expression	 studies	 with	 the	 trun-
cated	Kir6.2	pore	subunits	Kir6.2ΔC26	or	Kir6.2ΔC36,	which	form	
functional	 inwardly	 rectifying	K+	 channels	 in	 the	absence	of	SUR1	
subunits,	have	demonstrated	that	it	is	the	pore	construct	itself	that	
possesses the predominant binding site for all lipophilic drugs tested 
to	date:	detergents,24	imidazoles,20,25	barbiturates,26	pheniramines,27 
glitazones,7,28	 phenyl-	piperidinyl-	butyrophenones,29 quinolones6 
and	2-	n-	4-	benzoxazines,30	but	not	high-	affinity	sulphonylureas.22,23 
A	decrease	in	intracellular	Mg2+ is established to reduce the potency 
of	glitinides	and	sulphonylureas	to	inhibit	KATP activity but not that 
of other drugs2,4,22; an effect thought to be due to disruption of the 
interaction	between	 the	SUR1	and	Kir6.2	 subunits.	Consequently,	
F IGURE  2 Representative recordings 
of	single-	channel	KATP activity from 
primary mouse beta cells identified on 
basis	of	cell	morphology	and	block	by	
glucose. Openings are shown downward. 
A-	C,	Cell-	attached	recording	under	basal	
conditions	(A),	then	after	the	addition	
of	5	mmol/L	glucose	(B)	followed	by	
10 μmol/L	simvastatin	(C);	pipette	
potential	0	mV.	Note	decrease	in	single-	
channel current amplitude associated with 
depolarization of the plasma membrane 
potential.	D-	F,	Records	from	2	different	
inside-	out	patches	at	a	pipette	potential	
+70	mV.	D,	Control	record	and	then	after	
10 min in 10 μmol/L	simvastatin	(E).	F,	
Control record in a different patch and 
then	after	perifusion	of	0.1%	vol/vol	
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drug	 classes	which	 block	KATP channel activity with an IC50 unaf-
fected by Mg2+	are	those	already	shown	to	inhibit	KATP by a direct 
interaction	with	 the	Kir6.2	 pore	 subunit,	 notably	 the	 thiazolidine-
diones2,7,8; quinolones6,9; imidazoles2,9,20,25,31; disopyramide27; bar-
biturates12,26; detergents24; haloperidol29; fluoroquinolones10; 
2-	n-	hexyl-	4-	benzoxazines30; and terfenadine.2	As	the	block	of	KATP 
channel activity by simvastatin was also unaffected by intracellu-
lar	[Mg2+]i,	 it	supports	the	 idea	that	 its	block	of	KATP is by a direct 
interaction	with	the	Kir6.2	pore	subunit.	The	fact	that	neither	lipo-
phobic	pravastatin	(logP	0.59)	nor	DMSO	(logP	−1.35)	inhibited	KATP 
channel activity lends support to an intramembrane effect for sim-
vastatin and the other lipophilic drugs.
The	slowness	and	apparent	irreversibility	for	the	block	of	KATP by 
simvastatin	are	consistent	with	an	intramembrane	effect,	especially	as	
other	slow	blockers	of	KATP	of	similar	lipophilicity,	for	example	englita-
zone8	and	Triton	X-	100,24 are similarly slow in onset and irreversible. 
F IGURE  3 Effects	of	various	treatments	on	KATP	channel	activity	in	MIN6	cells.	A,	In	cell-	attached	mode	(CA-	Prefix):	10	μmol/L	
pravastatin	(CA-	Pra,	n	=	7)	and	its	H20	vehicle	control	(CA-	H20,	n	=	8);	10	μmol/L	simvastatin	(CA-	SimD,	n	=	9)	and	DMSO	vehicle	control	
(CA-	DMSO,	n	=	5);	10	μmol/L	simvastatin	(CA-	SimE,	n	=	10)	and	ethanol	vehicle	control	(CA-	ETOH,	n	=	5).	In	inside-	out	mode	(IO-	Prefix):	
10 μmol/L	simvastatin	(IO-	Sim,	n	=	8)	and	its	DMSO	vehicle	control	(IO-	DMSO,	n	=	5).	Data	mean	±	SD.	B,	Concentration-	effect	relationship	
for	the	block	of	KATP	channel	activity	(NPo)	in	inside-	out	patches	by	simvastatin	relative	to	basal.	Note	control	value	is	greater	than	unity	
due	to	“run	up”	of	channel	activity.	Data	are	mean	±	SD	(n	=	7-	8).	Solid	line	is	drawn	with	equation	1	using	values	given	in	the	text.	Dotted	
lines	are	the	95%	confidence	of	the	fit.	C,	Representative	whole-	cell	KATP current elicited by 10 mV steps of alternate polarity in response 
to	tolbutamide	(Tb)	and	simvastatin.	D,	Expansion	of	record	shown	in	(C)	showing	control	trace	and	effect	of	tolbutamide	(Tb,	bottom	
trace)	(E)	Individual	and	mean	values	(horizontal	lines)	for	the	block	of	whole-	cell	KATP by 20 μmol/L	tolbutamide	(Tb,	n	=	11),	100	nmol/L	
simvastatin	(SimL,	n	=	5)	and	1	μmol/L	simvastatin	(SimH,	n	=	3).	F,	Individual	and	mean	(horizontal	line)	for	the	IC50	of	whole-	cell	KATP	block	
by tolbutamide and for simvastatin calculated from the data shown in (E)
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What	is	surprising	is	that	logP,	a	facile	characteristic	of	a	drug	physico-
chemical	profile	and	considered	a	rudimentary	parameter	for	drug-	lipid	
bilayer	interactions,	is	sufficient	alone	to	predict	its	IC50	for	the	block	
of	KATP	without	the	need	to	revert	to	more	complex	QSAR.
Insight into the underlying mechanism by which simvastatin and 
the other compounds may affect channel function may be inferred 
from	the	action	of	genistein.	Genistein	is	an	isoflavonoid	that	blocks	
the	KATP	 current	of	 smooth	muscle	 (an	octamer	of	4	Kir6.x	and	4	
SUR2B)	with	an	IC50 of ~5.5 μmol/L,
32 a value that also lies within 
the	range	predicted	on	the	basis	of	its	logP	of	3.08	(1.8-	14	μmol/L;	
99%	C.I.).	Subsequent	studies	with	genistein	on	the	gating	of	grami-
cidin ion channel in model bilayer membranes have given rise to the 
F IGURE  4 Representative records 
for	the	effect	of	100	nmol/L	Simvastatin,	
DMSO and 20 μmol/L	tolbutamide	on	
intracellular Ca2+	within	single	MIN6	cells	
in	either	the	presence	(A-	C)	or	absence	
(D)	of	2	mmol/L	glucose.	Intracellular	
Ca2+ is normalized as a percentage of that 
measured	in	50	mmol/L	extracellular	K+ 
perifused	at	experiment	end.	A,	Addition	
of	tolbutamide	followed	by	a	10-	min	
wash before the addition of simvastatin. 
B,	Addition	of	simvastatin	followed	
by	a	10-	min	wash	before	the	addition	
of	tolbutamide.	C,	Addition	of	DMSO	
followed by the addition of tolbutamide. 
D,	Addition	of	tolbutamide	followed	by	
a	10-	min	wash	before	the	addition	of	
simvastatin in the absence of glucose
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idea that lipophilic compounds affect ion channel gating by altering 
the bilayer elastic properties and the ability of an ion channel to 
reorganize	 its	protein	 structure	during	gating	 transitions,33 in this 
case,	 leading	 to	 increased	occupancy	of	 the	closed	channel	 state:	
inhibition.
We	found	that,	in	the	absence	of	BSA,	100	nmol/L	simvastatin	
induced	an	increase	in	[Ca2+]i with temporal characteristics similar 
to	 those	 seen	with	 other	 drugs	 that	 block	 KATP channel activity 
and	stimulate	 insulin	secretion	such	as	tolbutamide;	however,	we	
did not observe stimulation of insulin secretion; a fact we ascribe 
due	to	sequestration	of	this	drug	by	serum	in	the	secretion	exper-
iments which substantially reduces its free concentration. In con-
trast,	 simvastatin	 concentrations	 of	 200	nmol/L	 and	 greater,	 but	
not	 pravastatin,	 have	 previously	 been	 shown	 to	 reversibly	 block	
glucose-	stimulated	Ca2+	 influx	and	 insulin	secretion	 in	pancreatic	
beta cells34;	an	action	explained	by	a	direct	block	of	L-	type	Ca2+ 
channels. Why Yada et al34	observed	simvastatin-	induced	changes	
in	glucose-	stimulated	insulin	secretion,	where	we	did	not,	remains	
a	 mystery.	 Although	 this	 difference	 may	 relate	 to	 them	 using	 a	
lower	concentration	of	serum;	however,	unfortunately,	they	do	not	
state the amount of serum used in this or in their previous papers.
At	therapeutic	levels,	0.1-	10	nmol/L,35 sequestration of simvas-
tatin	by	 serum	coupled	with	 its	 low	affinity	 for	 the	KATP channel 
probably	 explains	 why	 simvastatin	 does	 not	 cause	 a	 substantive	
block	 of	 this	 channel	 and	 hyperinsulinaemia	 during	 clinical	 use;	
moreover,	 the	 same	 argument	 also	 abrogates	 an	 interaction	 of	
statins	with	KATP	channels	as	an	explanation	for	the	adverse	meta-
bolic	actions	seen	with	chronic	use	of	these	drugs.	We	also	expect	
little	 effect	 on	 the	Kir6.2	pore	 subunit	 expressed	 in	 skeletal	 and	
cardiac	muscle,	as	 these	channels	are	majorly	closed	under	phys-
iological conditions.36	 To	 conclude,	 we	 demonstrate	 that	 logP,	 a	
measure	of	lipophilicity,	can	predict	the	potency	of	a	drug	to	block	
KATP	channels	without	the	need	to	consider	complex	quantitative	
structural activity relationships and suggest that the logP can be 
used	as	a	simple	aid	to	predict	the	potential	of	a	drug,	new	or	old,	
to	 inhibit	beta-	cell	KATP.	However,	whether	 such	drugs	cause	hy-
perinsulinaemia appears dependent on their absolute IC50 and free 
plasma concentration.
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F IGURE  5 Effects	of	various	treatments	on	insulin	secretion	and	KATP	channel	activity	(A-	B)	Effects	of	simvastatin	and	pravastatin	on	
insulin	secretion	normalized	to	total	islet	protein	content.	A,	Effect	of	100	nmol/L	of	drug	as	indicated,	on	basal	(1	mmol/L	glucose)	and	
11	mmol/L	glucose-	stimulated	insulin	secretion	(n	=	6	from	6	animals).	B,	Effect	of	1	μmol/L	of	drug	as	indicated,	on	basal	(2.8	mmol/L	
glucose)	and	11	mmol/L	glucose-	stimulated	insulin	secretion	(n	=	6	from	3	animals).	C,	Block	of	whole-	cell	KATP by simvastatin at the 
concentrations shown (μmol/L)	in	the	absence	or	presence	of	0.5%	(wt/vol)	BSA	(n	=	3-	5).	D,	Block	of	KATP	activity	measured	in	the	cell-	
attached patch configuration at the simvastatin concentrations shown (μmol/L)	either	in	the	absence	or	presence	of	0.1%	(wt/vol)	BSA	
(n	=	3-	11).	Data	are	mean	values	±	SD
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